---
title: "Tirabrutinib in Primary central nervous system lymphoma: Product information and disease description"
description: "Formulary evidence on Tirabrutinib in Primary central nervous system lymphoma: Product information and disease description. Covers Product description and Place of product in therapy. 67 evidence topics quoted from 38 sources."
canonical: "https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tirabrutinib in Primary central nervous system lymphoma: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### FDA orphan designation and approval status

> “Date Designated: 03/21/2023”
> “Orphan Designation: Treatment of primary central nervous system lymphoma”
> “FDA Orphan Approval Status: Not FDA Approved for Orphan Indication”

Source: [FDA Orphan Drug Designations and Approvals (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=930322)

<a id="topic-2.1.1-2"></a>

##### New drug application and FDA action date

> “accepted for filing”
> “under the accelerated approval pathway”
> “PDUFA Date of December 18, 2026”

Source: [Deciphera Pharmaceuticals (2026)](https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-us-food-and-drug-administration-acceptance-filing-new-drug)

<a id="topic-2.1.1-3"></a>

##### Regulatory status: Under review; NDA submitted December 2025 and accepted February 2026

> “As for VELEXBRU, as President Takino mentioned earlier, we filed an application in the US last December, and the application was accepted in February of this year.”

Source: [Ono Pharmaceutical (2026)](https://www.ono-pharma.com/sites/default/files/en/ir/library/financial_results/presen/script_20260508_en%5B.pdf)

> “Regarding tirabrutinib, which is currently under review for approval in the US, the PDUFA target date for the completion of the review is December 18 of this year.”
> “Regarding the review of tirabrutinib, yes, we are in the final stages of the review process”

Source: [Ono Pharmaceutical second quarter results presentation script (2026)](https://www.ono-pharma.com/sites/default/files/en/ir/library/financial_results/presen/script_20261029_en%23.pdf)

<a id="topic-2.1.1-4"></a>

##### Launch: Anticipated in the fiscal year ending March 2027

> “Next, I will discuss the full-year forecast for the fiscal year ending March 31, 2027.”
> “One of these, tirabrutinib, ONO-4059, is currently under review for approval by the US FDA. We are looking forward to this being our third global product as we prepare for its launch this fiscal year.”

Source: [Ono Pharmaceutical (2026)](https://www.ono-pharma.com/sites/default/files/en/ir/library/financial_results/presen/script_20260508_en%5B.pdf)

<a id="topic-2.1.1-5"></a>

##### Approval dates outside the United States

> “In Japan, tirabrutinib was approved in March 2020”
> “in South Korea in November 2021 and in Taiwan in February 2022.”

Source: [ONO Pharma USA (2023)](https://us.ono-pharma.com/news/tirabrutinib-receives-orphan-drug-designation)

<a id="topic-2.1.1-6"></a>

##### Taiwan assessment report: recorded approval date

> “2021/10/29”

Source: [Taiwan Food and Drug Administration assessment report](https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=40103&mid=189&t=s)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Deciphera Pharmaceuticals

> “Developed in collaboration with Deciphera’s parent company, Ono Pharma.”

Source: [Deciphera Pharmaceuticals](https://www.deciphera.com/pipeline)

> “Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd.”
> “The FDA’s acceptance of tirabrutinib’s NDA for filing is an exciting milestone as it brings us one step closer to our goal of providing patients with R/R PCNSL an important new treatment option.”
> “Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care.”

Source: [Deciphera Pharmaceuticals (2026)](https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-us-food-and-drug-administration-acceptance-filing-new-drug)

> “As of July 1, 2025, Key function of ONO PHARMA USA was integrated into Deciphera.”

Source: [ONO Pharma USA (2025)](https://us.ono-pharma.com/)

<a id="topic-2.1.2.1-2"></a>

###### Research name

> “Code name: ONO-4059”

Source: [National Cancer Institute Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tirabrutinib)

Additional sources: [Dhillon (2020)](https://pubmed.ncbi.nlm.nih.gov/32382949/)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Dosage form: Japan

> “Velexbru Tablets 80 mg”

Source: [PMDA review report (2020)](https://www.pmda.go.jp/files/000237315.pdf)

<a id="topic-2.1.2.2-2"></a>

###### Research-use chemical safety data sheet

> “Trade name: ONO-4059”
> “CAS Number: 1351636-18-4”
> “This product is for research use - Not for human or veterinary diagnostic or therapeutic use.”

Source: [Cayman Chemical safety data sheet (2025)](https://cdn.caymanchem.com/cdn/msds/32957m.pdf)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### United States average sales price and wholesale acquisition cost

No evidence found.

<a id="topic-2.1.2.3-2"></a>

###### Medical costs: Japan

> “Medical costs were calculated based on Japanese receipt scores.”
> “tirabrutinib cost 0.91 million JPY per month.”

Source: [Motomura et al. (2024)](https://academic.oup.com/jjco/article/54/10/1123/7747842)

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### ATC classification

> “L01EL06 Tirabrutinib”
> “L01EL Bruton's tyrosine kinase (BTK) inhibitors”

Source: [KEGG](https://www.kegg.jp/entry/D11070)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Approved indication: Taiwan

> “Relapsed or refractory B-cell primary central nervous system lymphoma in adult patients.”

Source: [Taiwan Food and Drug Administration assessment report](https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=40103&mid=189&t=s)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Covalent BTK binding

> “Upon administration, tirabrutinib covalently binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.”

Source: [National Cancer Institute Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tirabrutinib)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical evidence

> “In the TMD8 subcutaneous xenograft model, tirabrutinib showed a dose-dependent anti-tumor effect.”
> “Phosphoproteomic analysis revealed the downregulation of ERK and AKT pathways in TMD8.”

Source: [Kozaki et al. (2023)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0282166)

<a id="topic-2.1.2.6.2-2"></a>

###### Biochemical selectivity and off-target inhibition

> “Tirabrutinib irreversibly and covalently binds to BTK Cys-481.”

Source: [Liclican et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31953125/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetics: healthy subjects and rheumatoid arthritis

> “A biphasic PK profile was shown with median half-life ranging from ~ 6.2 to ~ 7.3 hours.”

Source: [Meng et al. (2022)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2439)

<a id="topic-2.1.2.6.3-2"></a>

###### Metabolism

> “The primary metabolic enzyme of tirabrutinib was CYP3A4 (in vitro).”

Source: [Taiwan Food and Drug Administration assessment report](https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=40103&mid=189&t=s)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Safety precautions: Japan

> “Oculomucocutaneous syndrome (Stevens-Johnson syndrome) or toxic epidermal necrolysis (TEN)”
> “Administration should be permanently discontinued.”

Source: [PMDA revision of precautions (2024)](https://www.pmda.go.jp/files/000269547.pdf)

<a id="topic-2.1.2.7.1-2"></a>

###### Toxic epidermal necrolysis: DLBCL case report

> “We present a case of a 74-year-old man with refractory DLBCL who developed TEN after 1 month of tirabrutinib treatment.”

Source: [Ikegawa et al. (2025)](https://academic.oup.com/skinhd/article/5/2/151/8106519)

<a id="topic-2.1.2.7.1-3"></a>

###### Skin-related adverse events across B-cell malignancies

> “PCNSL and WM patients were most susceptible to skin-related AEs.”

Source: [Wang et al. (2025)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1559056/full)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Hepatic impairment: caution in the Japanese review

> “careful use of tirabrutinib is essential for patients with hepatic impairment”

Source: [PMDA review report (2020)](https://www.pmda.go.jp/files/000237315.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Tirabrutinib

<a id="topic-2.1.2.9.1-1"></a>

###### CYP3A4 and P-glycoprotein interactions

> “Co-administration of the strong CYP3A4/P-gp inducer, rifampin, resulted in a significant decrease in tirabrutinib exposure (~70%).”
> “Co-administration of CYP3A4 inhibitors may increase tirabrutinib exposure.”

Source: [Gilead Sciences protocol GS-US-401-2076 (2019)](https://cdn.clinicaltrials.gov/large-docs/17/NCT02983617/Prot_000.pdf)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Tirabrutinib on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### In vitro CYP and transporter inhibition

> “In vitro data indicate tirabrutinib has the potential to inhibit several CYPs and transporters.”

Source: [Gilead Sciences protocol GS-US-401-2076 (2019)](https://cdn.clinicaltrials.gov/large-docs/17/NCT02983617/Prot_000.pdf)

<a id="topic-2.1.2.9.2-2"></a>

###### In vitro anthracycline interactions

> “Our in vitro data demonstrate that tirabrutinib influences daunorubicin pharmacodynamics by targeting both metabolic and transport pathways.”

Source: [Čermáková et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41297046/)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Usual adult dosage: Japan

> “The usual adult dosage is 480 mg of tirabrutinib administered orally once daily under fasting conditions.”

Source: [PMDA review report (2020)](https://www.pmda.go.jp/files/000237315.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Nasogastric administration and serum concentrations

> “Tirabrutinib concentrations may increase with nasogastric administration using the simple suspension method.”
> “In patients unable to ingest tablets orally, careful clinical monitoring is warranted, and therapeutic drug monitoring may be considered in select cases.”

Source: [Yashima et al. (2026)](https://academic.oup.com/ajhp/advance-article/doi/10.1093/ajhp/zxag190/8711514)

<a id="topic-2.1.2.10.2-2"></a>

###### Nasogastric administration in an elderly patient

> “We report that tirabrutinib was administered via nasogastric tubes to treat an elderly patient with primary central nervous system lymphoma (PCNSL).”

Source: [Yoshioka et al. (2021)](https://link.springer.com/article/10.1007/s13691-021-00491-1)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Marketed access: Japan

> “Tirabrutinib has been approved and is currently marketed in Japan for relapsed or refractory (R/R) PCNSL patients.”

Source: [PROSPECT study website](https://theprospectstudy.com/)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Investigational chemotherapy combinations: PROSPECT Part B

> “MTR: Methotrexate/ temozolomide/ rituximab”
> “R-MPV: Rituximab/ methotrexate/ procarbazine/ vincristine”

Source: [PROSPECT study website](https://theprospectstudy.com/)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Tirabrutinib on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Meta-analysis of tirabrutinib monotherapy across B-cell malignancies

> “seven clinical trials involving a total of 301 patients with CLL, PCNSL, MCL, and WM”

Source: [Wang et al. (2025)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1559056/full)

<a id="topic-2.1.2.14-2"></a>

###### Meta-analysis including tirabrutinib treatment regimens

> “Only two studies including 188 patients evaluated tirabrutinib-based treatment regimens”

Source: [Tan et al. (2025)](https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.70083)

Additional sources: [Zhang et al. (2024)](https://doi.org/10.3390/cancers16050860); [Guo et al. (2024)](https://www.sciencedirect.com/science/article/pii/S1878875024006302)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Disease definition

> “lymphoma limited to the cranial-spinal axis”
> “without systemic disease (stage IE)”

Source: [National Cancer Institute PDQ health professional version](https://www.cancer.gov/types/lymphoma/hp/primary-cns-lymphoma-treatment-pdq)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Primary central nervous system lymphoma

<a id="topic-2.2.1.2.1-1"></a>

###### United States epidemiology

> “Incidence rate increased from 0.1/100,000 to 0.5/100,000 with an AAPC of 5.3% from 1975 to 2017.”

Source: [Lv et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8793121/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Primary central nervous system lymphoma

No evidence found.

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Overall survival in published trials

> “the median overall survival in published trials generally ranges from 2 to 5 years.”

Source: [National Cancer Institute PDQ health professional version](https://www.cancer.gov/types/lymphoma/hp/primary-cns-lymphoma-treatment-pdq)

<a id="topic-2.2.1.3-2"></a>

###### Survival in older adults: United States registry analysis

> “The 5-year survival rate for elderly patients was about 30% in the 2010s.”

Source: [Lv et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8793121/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### B-cell histology

> “more than 95% of PCNSL cases are diffuse large B cell lymphoma (DLBCL)”

Source: [Chen et al. (2022)](https://link.springer.com/article/10.1186/s13045-022-01356-7)

<a id="topic-2.2.1.4-2"></a>

###### Immunosuppression and viral association

> “Immunosuppression-related primary CNS lymphomas are almost always associated with the Epstein-Barr virus.”

Source: [National Cancer Institute PDQ health professional version](https://www.cancer.gov/types/lymphoma/hp/primary-cns-lymphoma-treatment-pdq)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Histopathological confirmation

> “PCNSL diagnosis must be confirmed by histopathological examination of tumour biopsy”

Source: [Ferreri et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/hem3.89)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Neurological and gastrointestinal symptoms: headache, seizures, nausea, and vomiting

> “Signs and symptoms of primary CNS lymphoma may include nausea and vomiting or seizures.”
> “Headaches.”

Source: [National Cancer Institute PDQ patient version](https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq)

<a id="topic-2.2.1.6-2"></a>

###### Motor symptoms: limb weakness

> “Arm or leg weakness.”

Source: [National Cancer Institute PDQ patient version](https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq)

<a id="topic-2.2.1.6-3"></a>

###### Cognitive symptoms: confusion

> “Confusion.”

Source: [National Cancer Institute PDQ patient version](https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq)

<a id="topic-2.2.1.6-4"></a>

###### Visual and auditory symptoms

> “Double vision.”
> “Hearing loss.”

Source: [National Cancer Institute PDQ patient version](https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### High-dose brain radiation: possible cognitive and communication effects

> “can affect thinking, learning, problem solving, reading, writing, speech, and memory.”

Source: [National Cancer Institute PDQ patient version](https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Primary central nervous system lymphoma

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Long-term survivors: neuroimaging and quality of life after whole-brain radiotherapy

> “Total T2 abnormalities after WBRT were more than twice the mean of any non-WBRT group and were associated with poorer neuropsychological and QOL outcomes.”

Source: [Doolittle et al. (2013)](https://ohsu.elsevierpure.com/en/publications/long-term-cognitive-function-neuroimaging-and-quality-of-life-in--2/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### PCNSL economic burden: Taiwan

> “mean direct healthcare costs exceeding 1 million TWD (35,000 USD) concentrated within the first year following diagnosis.”

Source: [Hsiao et al. (2026a)](https://onlinelibrary.wiley.com/doi/10.1002/cam4.71707)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Primary central nervous system lymphoma on Families

No evidence found.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Stereotactic brain biopsy: Japanese medical costs

> “The cost of the stereotactic brain tumor biopsy surgery was 0.2 million JPY.”

Source: [Motomura et al. (2024)](https://academic.oup.com/jjco/article/54/10/1123/7747842)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Systemic Chemotherapy

<a id="topic-2.2.2.1.1-1"></a>

###### High-dose methotrexate: induction therapy

> “high-dose methotrexate is the most frequently used standard induction therapy.”

Source: [National Cancer Institute PDQ health professional version](https://www.cancer.gov/types/lymphoma/hp/primary-cns-lymphoma-treatment-pdq)

<a id="topic-2.2.2.1.1-2"></a>

###### Non-myeloablative consolidation regimen

> “cytarabine/etoposide”

Source: [Hoang-Xuan et al. (2023)](https://academic.oup.com/neuro-oncology/article-abstract/25/1/37/6661445)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Anti-CD20 Monoclonal Antibodies

<a id="topic-2.2.2.1.2-1"></a>

###### Rituximab-containing chemotherapy regimens

> “MTR: Methotrexate/ temozolomide/ rituximab”
> “R-MPV: Rituximab/ methotrexate/ procarbazine/ vincristine”

Source: [PROSPECT study website](https://theprospectstudy.com/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 High-dose Chemotherapy with Autologous Stem Cell Transplantation

<a id="topic-2.2.2.1.3-1"></a>

###### Thiotepa-based consolidation

> “consolidative HDC/ASCT, preferably conditioned by a thiotepa-based regimen”

Source: [Hoang-Xuan et al. (2023)](https://academic.oup.com/neuro-oncology/article-abstract/25/1/37/6661445)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Radiotherapy

<a id="topic-2.2.2.1.4-1"></a>

###### Whole-brain radiotherapy: salvage treatment

> “Salvage WBRT may be proposed in radiotherapy-naïve patients”

Source: [Hoang-Xuan et al. (2023)](https://academic.oup.com/neuro-oncology/article-abstract/25/1/37/6661445)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Bruton Tyrosine Kinase Inhibitors

<a id="topic-2.2.2.1.5-1"></a>

###### Relapsed or refractory PCNSL: EHA-ESMO guideline

> “Tirabrutinib, a highly selective BTK inhibitor, is a valid option in this setting.”

Source: [Ferreri et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/hem3.89)

<a id="topic-2.2.2.1.5-2"></a>

###### European Association of Neuro-Oncology guideline update

> “signs of clinical activity of tirabrutinib, a second-generation BTK inhibitor, have also been found.”

Source: [Hoang-Xuan et al. (2023)](https://academic.oup.com/neuro-oncology/article-abstract/25/1/37/6661445)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Immunomodulatory Agents

<a id="topic-2.2.2.1.6-1"></a>

###### Agents evaluated for relapsed or refractory disease

> “lenalidomide and pomalidomide”

Source: [Ferreri et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/hem3.89)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Intrathecal and Intravitreal Chemotherapy

<a id="topic-2.2.2.1.7-1"></a>

###### Local treatment for intraocular disease

> “Intravitreal MTX injections”

Source: [Ferreri et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/hem3.89)

<a id="topic-2.2.2.1.7-2"></a>

###### Combined intravenous and intrathecal treatment: cognitive-outcome literature

> “intravenous and intrathecal chemotherapy.”

Source: [Chen et al. (2022)](https://link.springer.com/article/10.1186/s13045-022-01356-7)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Immune Checkpoint Inhibitors

<a id="topic-2.2.2.1.8-1"></a>

###### Checkpoint inhibitor listed among active drugs for induction or relapsing disease

> “Nivolumab.”

Source: [National Cancer Institute PDQ health professional version](https://www.cancer.gov/types/lymphoma/hp/primary-cns-lymphoma-treatment-pdq)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 CAR T-cell Therapy

<a id="topic-2.2.2.1.9-1"></a>

###### Investigational salvage treatment: guideline evidence

> “CART have shown clinical activity”

Source: [Hoang-Xuan et al. (2023)](https://academic.oup.com/neuro-oncology/article-abstract/25/1/37/6661445)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Corticosteroids and Supportive Care

<a id="topic-2.2.2.1.10-1"></a>

###### Glucocorticoid antitumor activity

> “Glucocorticoids are steroid drugs that have an anticancer effect in lymphomas.”

Source: [National Cancer Institute PDQ patient version](https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq)

<a id="heading-2.2.2.1.11"></a>

###### 2.2.2.1.11 Limitations of Current Therapies

<a id="topic-2.2.2.1.11-1"></a>

###### Summary

The Chinese expert consensus reports no preferred standard regimen for relapsed or refractory PCNSL. Long-term survivor evidence links whole-brain radiotherapy with greater T2 abnormalities and poorer neuropsychological and quality-of-life outcomes. Thus, treatment selection must account for both disease control and treatment-related neurological burden; the cited survivorship findings do not establish the comparative safety of tirabrutinib.

Source: [Chen et al. (2022)](https://link.springer.com/article/10.1186/s13045-022-01356-7); [Doolittle et al. (2013)](https://ohsu.elsevierpure.com/en/publications/long-term-cognitive-function-neuroimaging-and-quality-of-life-in--2/)

<a id="topic-2.2.2.1.11-2"></a>

###### Unmet treatment needs

> “There is no standard regimen particularly preferred for relapsed/refractory (R/R) PCNSL.”

Source: [Chen et al. (2022)](https://link.springer.com/article/10.1186/s13045-022-01356-7)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

Tirabrutinib's established marketed use in the cited Japanese sources is relapsed or refractory PCNSL. The usual adult Japanese dosage is 480 mg orally once daily under fasting conditions. The EHA-ESMO guideline identifies tirabrutinib as an option in relapsed or refractory disease and recommends specialist multidisciplinary care. PROSPECT Part B investigates its addition to MTR or R-MPV in newly diagnosed PCNSL; that investigational use should not be treated as an approved first-line indication.

Source: [PROSPECT study website](https://theprospectstudy.com/); [PMDA review report (2020)](https://www.pmda.go.jp/files/000237315.pdf); [Ferreri et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/hem3.89)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Exploratory response subgroup: refractory after the last treatment

> “Those who were refractory after the last treatment (ORR, 33.3%)”

Source: [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Specialist multidisciplinary care

> “specialist centres by an experienced multidisciplinary team”

Source: [Ferreri et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/hem3.89)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

No evidence found.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

<a id="topic-2.2.2.6-1"></a>

###### Japanese approval condition: risk management

> “The applicant is required to develop and appropriately implement a risk management plan.”

Source: [PMDA review report (2020)](https://www.pmda.go.jp/files/000237315.pdf)

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Relapsed or refractory PCNSL: PROSPECT response and response duration

> “With an ORR of 66.7%, CR/CRu rate of 43.8%, median DOR of 9.3 mo”
> “median PFS was 6.0 mo”

Source: [Nayak et al. (2025a)](https://doi.org/10.1002/hon.70093_88)

## Related pages
- [Tirabrutinib: Primary central nervous system lymphoma](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Terms and abbreviations](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/terms-and-abbreviations.md)
- [Tirabrutinib: Primary central nervous system lymphoma](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/executive-summary.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Clinical evidence](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/clinical-evidence.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Economic information and modeling report](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/economics) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/economics.md)
- [Tirabrutinib in Primary central nervous system lymphoma: References](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/references) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/references.md)
- [Tirabrutinib in Primary central nervous system lymphoma: prevalence by geography](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/prevalence) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/prevalence.md)
- [Tirabrutinib in Primary central nervous system lymphoma: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/cost-effectiveness-analyses.md)
